These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
810 related articles for article (PubMed ID: 25527356)
21. The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome. Arias-Pulido H; Cimino-Mathews A; Chaher N; Qualls C; Joste N; Colpaert C; Marotti JD; Foisey M; Prossnitz ER; Emens LA; Fiering S Breast Cancer Res Treat; 2018 Sep; 171(2):273-282. PubMed ID: 29858752 [TBL] [Abstract][Full Text] [Related]
22. The Therapeutic Effectiveness of Neoadjuvant Trastuzumab Plus Chemotherapy for HER2-Positive Breast Cancer Can Be Predicted by Tumor-Infiltrating Lymphocytes and PD-L1 Expression. Shang M; Chi Y; Zhang J; Chang J; Yang H; Yin S; Tan Q; Man X; Li H Front Oncol; 2021; 11():706606. PubMed ID: 35070953 [TBL] [Abstract][Full Text] [Related]
23. Evaluation of PD-L1, tumor-infiltrating lymphocytes, and CD8+ and FOXP3+ immune cells in HER2-positive breast cancer treated with neoadjuvant therapies. Zhao J; Meisel J; Guo Y; Nahta R; Hsieh KL; Peng L; Wei Z; O'Regan R; Li X Breast Cancer Res Treat; 2020 Oct; 183(3):599-606. PubMed ID: 32715443 [TBL] [Abstract][Full Text] [Related]
24. Early Stage HER2-Positive Breast Cancers Not Achieving a pCR From Neoadjuvant Trastuzumab- or Pertuzumab-Based Regimens Have an Immunosuppressive Phenotype. Force J; Howie LJ; Abbott SE; Bentley R; Marcom PK; Kimmick G; Westbrook K; Sammons SL; Parks M; Topping DL; Emerson R; Broadwater G; Hyslop T; Blackwell KL; Nair SK Clin Breast Cancer; 2018 Oct; 18(5):410-417. PubMed ID: 29615305 [TBL] [Abstract][Full Text] [Related]
25. Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer. Kurozumi S; Fujii T; Matsumoto H; Inoue K; Kurosumi M; Horiguchi J; Kuwano H Med Mol Morphol; 2017 Dec; 50(4):185-194. PubMed ID: 28936553 [TBL] [Abstract][Full Text] [Related]
26. Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer. McLaughlin J; Han G; Schalper KA; Carvajal-Hausdorf D; Pelekanou V; Rehman J; Velcheti V; Herbst R; LoRusso P; Rimm DL JAMA Oncol; 2016 Jan; 2(1):46-54. PubMed ID: 26562159 [TBL] [Abstract][Full Text] [Related]
28. Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study. Sarradin V; Lusque A; Filleron T; Dalenc F; Franchet C Breast Cancer Res; 2021 May; 23(1):61. PubMed ID: 34039396 [TBL] [Abstract][Full Text] [Related]
29. Prediction of Treatment Response to Neoadjuvant Chemotherapy in Breast Cancer by Subtype Using Tumor-infiltrating Lymphocytes. Asano Y; Kashiwagi S; Goto W; Takada K; Takahashi K; Hatano T; Takashima T; Tomita S; Motomura H; Ohsawa M; Hirakawa K; Ohira M Anticancer Res; 2018 Apr; 38(4):2311-2321. PubMed ID: 29599354 [TBL] [Abstract][Full Text] [Related]
30. Expression of programmed cell death ligand 1 and immune checkpoint markers in residual tumors after neoadjuvant chemotherapy for advanced high-grade serous ovarian cancer. Kim HS; Kim JY; Lee YJ; Kim SH; Lee JY; Nam EJ; Kim S; Kim SW; Kim YT Gynecol Oncol; 2018 Dec; 151(3):414-421. PubMed ID: 30314669 [TBL] [Abstract][Full Text] [Related]
31. Infiltrating stromal immune cells in inflammatory breast cancer are associated with an improved outcome and increased PD-L1 expression. Van Berckelaer C; Rypens C; van Dam P; Pouillon L; Parizel M; Schats KA; Kockx M; Tjalma WAA; Vermeulen P; van Laere S; Bertucci F; Colpaert C; Dirix L Breast Cancer Res; 2019 Feb; 21(1):28. PubMed ID: 30777104 [TBL] [Abstract][Full Text] [Related]
32. PD-L1 Acts as a Promising Immune Marker to Predict the Response to Neoadjuvant Chemotherapy in Breast Cancer Patients. Du Q; Che J; Jiang X; Li L; Luo X; Li Q Clin Breast Cancer; 2020 Feb; 20(1):e99-e111. PubMed ID: 31521537 [TBL] [Abstract][Full Text] [Related]
33. PD-L1 Expression in TNBC: A Predictive Biomarker of Response to Neoadjuvant Chemotherapy? Cerbelli B; Pernazza A; Botticelli A; Fortunato L; Monti M; Sciattella P; Campagna D; Mazzuca F; Mauri M; Naso G; Marchetti P; d'Amati G; Costarelli L Biomed Res Int; 2017; 2017():1750925. PubMed ID: 29387716 [TBL] [Abstract][Full Text] [Related]
34. Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases. Berghoff AS; Ricken G; Widhalm G; Rajky O; Dieckmann K; Birner P; Bartsch R; Höller C; Preusser M Histopathology; 2015 Jan; 66(2):289-99. PubMed ID: 25314639 [TBL] [Abstract][Full Text] [Related]
35. Tumor-infiltrating lymphocytes in breast cancer predict the response to chemotherapy and survival outcome: A meta-analysis. Wang K; Xu J; Zhang T; Xue D Oncotarget; 2016 Jul; 7(28):44288-44298. PubMed ID: 27329588 [TBL] [Abstract][Full Text] [Related]
36. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy. Tokito T; Azuma K; Kawahara A; Ishii H; Yamada K; Matsuo N; Kinoshita T; Mizukami N; Ono H; Kage M; Hoshino T Eur J Cancer; 2016 Mar; 55():7-14. PubMed ID: 26771872 [TBL] [Abstract][Full Text] [Related]